FLT-3 inhibitor: A gene-targeted therapy for a common subtype of acute myeloid leukemia (AML) known as FLT-positive AML in which there is a FLT3 receptor mutation. The FLT-3 inhibitor is a tyrosine kinase inhibitor that interferes with abnormal FLT3 function by preventing essential proteins from binding to the DNA. The FLT-3 inhibitor blocks the action of the altered FLT-3 gene, rendering it powerless. Sorafenib and others are in clinical trials as FLT-3 inhibitors for AML.
Reviewed on 12/21/2018
CONTINUE SCROLLING FOR RELATED SLIDESHOW